A5062634793- CAR-T cell therapy research
- PARP inhibition in cancer therapy
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Connexins and lens biology
- Toxin Mechanisms and Immunotoxins
- Bladder and Urothelial Cancer Treatments
- Neuroblastoma Research and Treatments
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Immunotherapy and Immune Responses
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Melanoma and MAPK Pathways
- Multiple and Secondary Primary Cancers
- Statistical Methods in Clinical Trials
- Monoclonal and Polyclonal Antibodies Research
- Chronic Lymphocytic Leukemia Research
- Cell death mechanisms and regulation
- Urinary and Genital Oncology Studies
- Bacillus and Francisella bacterial research
- Neuroendocrine Tumor Research Advances
- Neutropenia and Cancer Infections
Takeda (United States)
2018-2022
Sanofi (Spain)
2012-2019
Millennium Engineering and Integration (United States)
2018
AVEO Oncology (United States)
2015
Sanofi (United States)
2015
Tennessee Oncology
2014
Virginia Oncology Associates
2014
Texas Oncology
2014
Sarah Cannon
2014
Eli Lilly (Netherlands)
2009-2011
Purpose There is a lack of treatments providing survival benefit for patients with metastatic triple-negative breast cancer (mTNBC), no standard care. A randomized phase II trial showed significant gemcitabine, carboplatin, and iniparib (GCI) over gemcitabine carboplatin (GC) in clinical rate, response progression-free (PFS), overall (OS). Here, we formally compare the efficacy these regimens III trial. Patients Methods stage IV/locally recurrent TNBC who had received more than two previous...
Several randomized trials have tested the use of granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage (GMCSF) in relieving chemotherapy-induced bone marrow suppression. However, CSFs treatment neutropenic fever remains virtually unexplored. This study evaluated benefits adding CSF therapy to standard antibiotic treatments given cancer patients for fever. The usefulness was quantified terms reducing following: ( a ) duration neutropenia, b length hospitalization, c overall...
Abstract Purpose: LY2334737 is an orally available prodrug of gemcitabine. The objective this study was to determine the maximum tolerated dose (MTD) and limiting toxicities (DLT) daily administration with or without erlotinib. Experimental Design: Patients advanced metastatic cancer were treated escalating doses monotherapy in combination continuous 100 mg given once for 14 days a 21-day cycle. extended bioequivalence trial investigate novel drug formulation. Results: A total 65 patients...
Interleukin (IL)-1 signaling has an essential role in tumor progression and immunosuppression is linked to acquired resistance anti-PD-1/PD-L1 treatment. Nadunolimab IL1RAP (IL-1 receptor accessory protein)-targeting antibody that blocks IL-1α/IL-1β enhanced antibody-dependent cellular cytotoxicity. We investigated the safety preliminary efficacy of nadunolimab with pembrolizumab patients metastatic solid tumors who had progressed on previous checkpoint inhibitor treatment, suggesting...
Abstract Gemcitabine is a nucleoside analogue with anticancer activity. Inside the cell, it sequentially phosphorylated to generate active drug. Phosphorylated analogues have been shown traffic through gap junctions. We investigated participation of junctional intercellular communication (GJIC) as possible mechanism spreading gemcitabine cytotoxicity in pancreatic tumors. Immunohistochemical analysis cancer biopsies revealed increased connexin 26 (Cx26) content but loss connexins 32 (Cx32)...
The herpes simplex virus-thymidine kinase/ganciclovir (HSVtk/GCV) system produces both direct and immune-mediated tumor cell killing. Here, we compare the efficacy of HSVtk/GCV with cytokines, alone in combination, on tumorigenicity immunogenicity B16 cells. With respect to single gene modifications, only HSVtk/GCV, or high-level interleukin-2 (IL-2) secretion, completely prevented growth, whereas granulocyte-macrophage colony-stimulating factor (GM-CSF) generated best levels long-term...
No AccessJournal of UrologyAdult Urology: Oncology: Renal/Upper Tract/Bladder1 Aug 2004PHASE I PHARMACOKINETIC STUDY OF A SINGLE INTRAVESICAL INSTILLATION GEMCITABINE ADMINISTERED IMMEDIATELY AFTER TRANSURETHRAL RESECTION PLUS MULTIPLE RANDOM BIOPSIES IN PATIENTS WITH SUPERFICIAL BLADDER CANCER JUAN PALOU, ANTONIO CARCAS, JOSE SEGARRA, BLANCA DUQUE, SALVADOR, IGNACIO GARCIA-RIBAS, and HUMBERTO VILLAVICENCIO PALOUJUAN PALOU More articles by this author , CARCASANTONIO CARCAS SEGARRAJOSE...
The investigation of genetic alterations that may be related to the prognosis patients with malignant disease has become a frequently used strategy in recent years. Although some conclusions have been reached certain studies, complexity and multifactorial nature most neoplastic diseases makes it difficult identify clinically relevant information, results studies borderline significance or conflicting. In contrast, identification study families very characteristic phenotypes yielded...
We conducted a first-in-human, dose-escalation study, to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and activity of TAK-931, cell division cycle 7 inhibitor, in Japanese patients with advanced solid tumors.Patients ages ≥20 years received oral TAK-931: once daily for 14 days 21-day cycles (schedule A; from 30 mg); or twice on, off 28-day B; 60 continuous D; 20 2 5 E; 100 mg) cycles.Of 80 enrolled, all had prior systemic treatment 86% stage IV disease. In schedule...
1011 Background: Iniparib is an anticancer agent with a mechanism of action still under investigation. A phase 2 randomized neoadjuvant study in patients (pts) TNBC was designed to explore the activity and tolerability two schedules iniparib weekly paclitaxel (PTX). Here we report efficacy safety results from planned interim analysis (IA). Methods: The trial accrued total 141 pts October 2011, whom, 74 are included this IA. All were chemo-naive, histologicallyconfirmed Stage II-IIIA (IIA...
9020 Background: Interleukin-1 Receptor Accessory Protein (IL1RAP) is expressed by cancer and stromal cells of many solid tumors. The IL-1 pathway active in tumors upregulated response to chemotherapy. IL1RAP interacts with IL-1R1 modulates downstream factors (e.g. IL-6, IL-8) CRP level. Nadunolimab (CAN04), a fully humanized ADCC-enhanced IgG1 antibody, targets blocks IL-1α IL-1β signaling. Here, results are reported from the phase 1/2a clinical trial CANFOUR evaluating nadunolimab combined...
4141 Background: Interleukin-1 Receptor Accessory Protein (IL1RAP) is expressed on cancer and stromal cells in PDAC. The IL-1 pathway active the pancreatic tumor microenvironment upregulated response to chemotherapy. IL1RAP interacts with IL-1R1 modulates downstream factors (e.g. IL-6, IL-8) CRP level. Nadunolimab (CAN04), a fully humanized ADCC-enhanced IgG1 antibody, targets blocks IL-1α IL-1β signaling. Here, results are reported from phase 1/2a clinical trial CANFOUR evaluating...
580
Aim & methods: A retrospective study using the IBM Explorys Universe Database assessed risk of gastrointestinal events (enterocolitis or diarrhea) among melanoma and lung cancer patients treated with ipilimumab nivolumab combination monotherapy. Results conclusion: There were 904 (607 ipilimumab, 140 157 combo) 1641 (68 1542 31 combo). Approximately, 37% 46% experienced at least one adverse event. After adjusting for covariates, receiving therapy more likely to have a event compared...
4544 Background: Although cisplatin is considered the cornerstone for treatment of advanced bladder cancer, up to 50% patients (pts) cannot receive it because they are unfit mainly due poor renal function. New non nephrotoxic regimens needed. Gemcitabine and oxaliplatin active, non-nephrotoxic with non-overlapping toxicity therefore being attractive be studied in combination cancer patients. Methods: Thirty-six pts (mainly function,creatinine clearance < 60 mL/min) standard cisplatin-based...
4544 Background: Although cisplatin is considered the cornerstone for treatment of advanced bladder cancer, up to 50% patients (pts) cannot receive it because they are unfit mainly due poor renal function. New non nephrotoxic regimens needed. Gemcitabine and oxaliplatin active, non-nephrotoxic with non-overlapping toxicity therefore being attractive be studied in combination cancer patients. Methods: Thirty-six pts (mainly function,creatinine clearance < 60 mL/min) standard cisplatin-based...
Interleukin (IL)-1 pathway upregulation is implicated in pancreatic ductal adenocarcinoma (PDAC) progression, therapy resistance, and survival. Nadunolimab an IL-1 receptor accessory protein (IL1RAP)-targeting antibody with enhanced antibody-dependent cellular cytotoxicity that blocks IL-1α/IL-1β signaling. We investigated efficacy safety of nadunolimab PDAC, combination gemcitabine/nab-paclitaxel (GN).
<div>AbstractPurpose:<p>IL1 pathway upregulation is implicated in pancreatic ductal adenocarcinoma (PDAC) progression, therapy resistance, and survival. Nadunolimab an IL1 receptor accessory protein (IL1RAP)–targeting antibody with enhanced antibody-dependent cellular cytotoxicity that blocks IL1α/IL1β signaling. We investigated efficacy safety of nadunolimab PDAC, combination gemcitabine/nab-paclitaxel (GN).</p>Patients Methods:<p>Patients previously untreated...
<p>Supplementary methods and results</p>